Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen

详细信息    查看全文

• 作者：Ze-jun Lu (1)
  Qi-fang Song (1) (2)
  Sa-sa Jiang (1)
  Qi Song (3)
  Wei Wang (1)
  Gao-hua Zhang (1)
  Bin Kan (1)
  Lan-tu Gou (1)
  Li-juan Chen (1)
  Feng Luo (1)
  Zhi Yong Qian (1)
  Jin-liang Yang (1)
  Yu Quan Wei (1)
  
• 刊名：BMC Cancer
• 出版年：2009
• 出版时间：December 2009
• 年：2009
• 卷：9
• 期：1
• 全文大小：1806KB
• 参考文献：1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. / CA Cancer J Clin 2008, 58: 71鈥?6. CrossRef
  2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK: Annual report to the nation on the status of cancer, 1975鈥?000, featuring the uses of surveillance data for cancer prevention and control. / J Natl Cancer Inst 2003, 95: 1276鈥?299.
  3. Breedveld FC: Therapeutic monoclonal antibodies. / Lancet 2000, 355: 735鈥?40. CrossRef
  4. Rossi A, Bria E, Maione P, Palazzolo G, Falanga M, Gridelli C: The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer. / Rev Recent Clin Trials 2008, 3: 217鈥?27. CrossRef
  5. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C: A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). / Ann Oncol 2006, 17: 1007鈥?013. CrossRef
  6. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS: Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. / Lung Cancer 2004, 44: 99鈥?10. CrossRef
  7. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. / J Clin Oncol 2004, 22: 2184鈥?191. CrossRef
  8. Mu XL, Li LY, Zhang XT, Wang SL, Wang MZ: Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. / BMC Cancer 2004, 4: 51. CrossRef
  9. Copeman M: Prolonged response to first-line erlotinib for advanced lung adenocarcinoma. / J Exp Clin Cancer Res 2008, 27: 59. CrossRef
  10. Ning Y, Wang Y, Li Y, Hong Y, Peng D, Liu Y, Wang J, Hao W, Tian X, Wu F, Dong W, Wang L, Wu Q, Liu X, Gao J, He F, Qian X, Sun QH, Li M: An alternative strategy for high throughput generation and characterization of monoclonal antibodies against human plasma proteins using fractionated native proteins as immunogens. / Proteomics 2006, 6: 438鈥?48. CrossRef
  11. Boyer PD: The ATP synthase鈥揳 splendid molecular machine. / Annu Rev Biochem 1997, 66: 717鈥?49. CrossRef
  12. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, Cheek DJ, Pizzo SV: Endothelial cell surface F1鈥揊0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. / Proc Natl Acad Sci USA 2001, 98: 6656鈥?661. CrossRef
  13. Arakaki N, Nagao T, Niki R, Toyofuku A, Tanaka H, Kuramoto Y, Emoto Y, Shibata H, Magota K, Higuti T: Possible role of cell surface H+ -ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. / Mol Cancer Res 2003, 1: 931鈥?39.
  14. Chi SL, Pizzo SV: Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. / Cancer Res 2006, 66: 875鈥?82. CrossRef
  15. Moser TL, Stack MS, Asplin I, Enghild JJ, H酶jrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV: Angiostatin binds ATP synthase on the surface of human endothelial cells. / Proc Natl Acad Sci USA 1999, 96: 2811鈥?816. CrossRef
  16. Zhao Y, Zhang W, Kho Y, Zhao Y: Proteomic analysis of integral plasma membrane proteins. / Anal Chem 2004, 76: 1817鈥?823. CrossRef
  17. Champagne E, Martinez LO, Collet X, Barbaras R: Ecto-F1Fo ATP synthase/F1 ATPase: metabolic and immunological functions. / Curr Opin Lipidol 2006, 17: 279鈥?84. CrossRef
  18. Chi SL, Pizzo SV: Cell surface F1Fo ATP synthase: a new paradigm? / Ann Med 2006, 38: 429鈥?38. CrossRef
  19. Jung KH, Song SH, Paik JY, Koh BH, Choe YS, Lee EJ, Kim BT, Lee KH: Direct targeting of tumor cell F(1)F(0) ATP-synthase by radioiodine angiostatin in vitro and in vivo. / Cancer Biother Radiopharm 2007, 22: 704鈥?12. CrossRef
  20. Das B, Mondragon MO, Sadeghian M, Hatcher VB, Norin AJ: A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines. / J Exp Med 1994, 180: 273鈥?81. CrossRef
  21. Veitonm盲ki N, Cao R, Wu LH, Moser TL, Li B, Pizzo SV, Zhivotovsky B, Cao Y: Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1鈥?-induced antiangiogenesis. / Cancer Res 2004, 64: 3679鈥?686. CrossRef
  22. Chi SL, Wahl ML, Mowery YM, Shan S, Mukhopadhyay S, Hilderbrand SC, Kenan DJ, Lipes BD, Johnson CE, Marusich MF, Capaldi RA, Dewhirst MW, Pizzo SV: Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. / Cancer Res 2007, 67: 4716鈥?724. CrossRef
  23. Kenan DJ, Wahl ML: Ectopic localization of mitochondrial ATP synthase: a target for anti-angiogenesis intervention? / J Bioenerg Biomembr 2005, 37: 461鈥?65. CrossRef
  24. Hanash SM, Madoz-Gurpide J, Misek DE: Identification of novel targets for cancer therapy using expression proteomics. / Leukemia 2002, 16: 478鈥?85. CrossRef
  25. Gao J, Gao Y, Ju Y, Yang J, Wu Q, Zhang J, Du X, Wang Z, Song Y, Li H, Luo X, Ren F, Li J, Chen Y, Wang L, Xu H, Liu X, Wang J, Zhang Y, Cai Y, Cui Y, Qian X, He F, Li M, Sun QH: Proteomics-based generation and characterization of monoclonal antibodies against human liver mitochondrial proteins. / Proteomics 2006, 6: 427鈥?37. CrossRef
  26. Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD: Towards proteome-wide production of monoclonal antibody by phage display. / J Mol Biol 2002, 315: 1063鈥?073. CrossRef
  27. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/16/prepub
  
• 作者单位：Ze-jun Lu (1)
  Qi-fang Song (1) (2)
  Sa-sa Jiang (1)
  Qi Song (3)
  Wei Wang (1)
  Gao-hua Zhang (1)
  Bin Kan (1)
  Lan-tu Gou (1)
  Li-juan Chen (1)
  Feng Luo (1)
  Zhi Yong Qian (1)
  Jin-liang Yang (1)
  Yu Quan Wei (1)
  
  1. Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Xiang Street, 610041, Chengdu, Sichuan, PR China
  2. College of Life Science and Technology, Jinan Uuniversity, 510632, Guangzhou, PR China
  3. West China Maternal and Children Hospital, Sichuan University, 37 Guoxue Xiang Street, 610041, Chengdu, Sichuan, PR China
  
• ISSN：1471-2407

文摘

Background Antibody-based immuneotherapy has achieved some success for cancer. But the main problem is that only a few tumor-associated antigens or therapeutic targets have been known to us so far. It is essential to identify more immunogenic antigens (especially cellular membrane markers) for tumor diagnosis and therapy. Methods The membrane proteins of lung adenocarcinoma cell line A549 were used to immunize the BALB/c mice. A monoclonal antibody 4E7 (McAb4E7) was produced with hybridoma technique. MTT cell proliferation assay was carried out to evaluate the inhibitory effect of McAb4E7 on A549 cells. Flow cytometric assay, immunohistochemistry, western blot and proteomic technologies based on 2-DE and mass spectrometry were employed to detect and identify the corresponding antigen of McAb4E7. Results The monoclonal antibody 4E7 (McAb4E7) specific against A549 cells was produced, which exhibited inhibitory effect on the proliferation of A549 cells. By the proteomic technologies, we identified that ATP synthase beta subunit (ATPB) was the corresponding antigen of McAb4E7. Then, flow cytometric analysis demonstrated the localization of the targeting antigen of McAb4E7 was on the A549 cells surface. Furthermore, immunohistochemstry showed that the antigen of McAb4E7 mainly aberrantly expressed in tumor cellular membrane in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC). The rate of ectopic expressed ATPB in the cellular membrane in lung adenocarcinoma, squamous carcinoma and their adjacent nontumourous lung tissues was 71.88%, 66.67% and 25.81% respectively. Conclusion In the present study, we identified that the ectopic ATPB in tumor cellular membrane was the non-small cell lung cancer (NSCLC) associated antigen. ATPB may be a potential biomarker and therapeutic target for the immunotherapy of NSCLC.